Understanding Cannabis-Induced Psychosis: Risks, Challenges, and Treatment Approaches

Location: Flores 4-5 Session Description: With the growing popularity and legalization of cannabis, there has been a rise in the number of individuals experiencing cannabis-induced psychosis, either following prolonged or short-term cannabis use. The primary active component of cannabis, delta 9-tetrahydrocannabinol (delta9-THC), plays a crucial role in this phenomenon.

This workshop aims to shed light on the distinctive risk of chronic residual psychosis among cannabis users who have experienced acute psychotic episodes, which differs from the diagnosis of schizophrenia or other psychotic disorders. Furthermore, it will explore the unique challenges faced when treating this specific population and delve into medication approaches for managing chronic psychotic symptoms.

As the legalization of marijuana continues to expand to more states, and accessibility to cannabis becomes more widespread, the prevalence of cannabis-related disorders is expected to further increase. Consequently, the workshop will also emphasize the importance of advocating against cannabis use and provide strategies for discouraging its consumption.